BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 12901225)

  • 1. Telomerase inhibitors in cancer therapy: current status and future directions.
    Incles CM; Schultes CM; Neidle S
    Curr Opin Investig Drugs; 2003 Jun; 4(6):675-85. PubMed ID: 12901225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
    Kelland LR
    Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
    Tárkányi I; Aradi J
    Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
    Raymond E; Faivre S; Dieras V; Von Hoff D
    Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting telomeres and telomerase.
    De Cian A; Lacroix L; Douarre C; Temime-Smaali N; Trentesaux C; Riou JF; Mergny JL
    Biochimie; 2008 Jan; 90(1):131-55. PubMed ID: 17822826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The telomeric PARP, tankyrases, as targets for cancer therapy.
    Seimiya H
    Br J Cancer; 2006 Feb; 94(3):341-5. PubMed ID: 16421589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Telomere and telomerase in human cancer].
    Hiyama K; Hiyama E; Ishioka S; Yamakido M
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):196-201. PubMed ID: 9030230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomeres, telomerase and cancer: is the magic bullet real?
    Sharma HW; Maltese JY; Zhu X; Kaiser HE; Narayanan R
    Anticancer Res; 1996; 16(1):511-5. PubMed ID: 8615664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase as a target for cancer therapy.
    Parkinson KE
    Curr Opin Investig Drugs; 2005 Jun; 6(6):605-10. PubMed ID: 15988912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomeres and telomerase as targets for anticancer drug development.
    Olaussen KA; Dubrana K; Domont J; Spano JP; Sabatier L; Soria JC
    Crit Rev Oncol Hematol; 2006 Mar; 57(3):191-214. PubMed ID: 16469501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
    Seimiya H; Muramatsu Y; Ohishi T; Tsuruo T
    Cancer Cell; 2005 Jan; 7(1):25-37. PubMed ID: 15652747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532).
    El Daly H; Martens UM
    Methods Mol Biol; 2007; 405():47-60. PubMed ID: 18369817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway.
    Kelland L
    Clin Cancer Res; 2007 Sep; 13(17):4960-3. PubMed ID: 17785545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tackling cancer at the telomeres.
    Marx J
    Science; 2002 Mar; 295(5564):2350. PubMed ID: 11923505
    [No Abstract]   [Full Text] [Related]  

  • 15. Telomere biology of pediatric cancer.
    Tabori U; Dome JS
    Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomeres rather than telomerase a key target for anti-cancer therapy?
    Boukamp P; Mirancea N
    Exp Dermatol; 2007 Jan; 16(1):71-9. PubMed ID: 17181645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells.
    Gomez-Millan J; Goldblatt EM; Gryaznov SM; Mendonca MS; Herbert BS
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):897-905. PubMed ID: 17175117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer therapy targeting telomeres and telomerase : current status.
    Parkinson EK; Minty F
    BioDrugs; 2007; 21(6):375-85. PubMed ID: 18020621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomere inhibition and telomere disruption as processes for drug targeting.
    Rezler EM; Bearss DJ; Hurley LH
    Annu Rev Pharmacol Toxicol; 2003; 43():359-79. PubMed ID: 12540745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of 3'-azido-2',3'-dideoxyguanosine treatment on telomere length in human telomerase-immortalized human fibroblast cells.
    Kurashina Y; Liu X; Kato C; Inoue N; Saneyoshi M; Yamaguchi T
    Nucleic Acids Symp Ser (Oxf); 2009; (53):249-50. PubMed ID: 19749354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.